

New

Private Companies Report from The Freedonia Group

Freedonia

Biotechnology



Pharmaceuticals

Report # 1363

December 2000

\$ 3200

Key Findings:

- Hundreds of private and start-up firms are pursuing pharmaceutical biotechnology growth opportunities through research in advanced medicines that offer significant improvements over existing therapies.
- In 1999, two private and start-up firms had total biotechnology pharmaceutical product and/or service revenues in excess of \$50 million.
- Smaller private and start-up firms are able to meet the substantial funding requirements necessary to compete in the industry, often by receiving equity investments from drug makers or by issuing initial public offerings.
- While a few private and start-up biotechnology pharmaceutical firms concentrate on a single drug target area, most are active in research spanning multiple indications, largely due to the broad application potential of the major technologies.
- Among private and start-up companies, participation is greatest in the development of therapies for cancer, diabetes, central nervous system disorders and cardiovascular disorders.
- California and Massachusetts have the largest numbers of private and start-up biotechnology pharmaceutical operations, with over 150 each. Other leading states include Colorado, Illinois, Maryland, New Jersey, New York, North Carolina, Pennsylvania, Texas and Washington.
- Demand for biotechnology pharmaceuticals in the US is expected to increase 13 percent annually to \$28.6 billion in 2004.

Report Features

This report profiles 110+ privately-held and start-up US companies developing and/or producing biotechnology-based pharmaceuticals, as well as drug discovery technologies, and assesses the role these companies play within the industry. Each company profiled was interviewed regarding their product lines, sales and/or employment.

Market Overview — presents the economic factors which will dictate growth in the US biotechnology pharmaceuticals market, and contains Freedonia industry demand forecasts to 2004.

Industry Structure — identifies the leading private and public companies in the biotechnology pharmaceuticals industry, and analyzes private company merger and acquisition, and IPO activity. The report also contains listings of private and start-up firms by key product and state.

Company Profiles — the main body of the report profiles privately-held and start-up companies active in the industry.

Report Benefits

Save hours of time researching difficult to find private company information and identifying players in key product and market segments. Freedonia has used its vast resources of published and proprietary information, as well as one-on-one interviews, to identify and profile more than 110 privately-held and start-up companies in a specific industry. Companies are organized by product and/or market in easy-to-read tables.

Identify companies for investment, merger, and/or acquisition opportunities based on size, products, and location.

Understand barriers to entry based on industry concentration and market shares.

Measure your market and sales potential based on demand forecasts.

Develop strategies based on size and geographic location of competitors.

Preliminary Table of Contents

Introduction

EXECUTIVE SUMMARY

MARKET OVERVIEW

- General
 - Health Care Trends
 - Pharmaceutical Industry Trends
 - Regulatory Factors
- Biotechnology Pharmaceuticals Outlook
 - Product Types
 - Technologies
 - Indications

INDUSTRY STRUCTURE

- General
- Consolidation Trends & Recent Acquisitions
- IPO Activity
- Market Share
- Private & Start-Up Company Characteristics
 - AIDS/HIV Biotechnology Pharmaceuticals
 - Cancer Biotechnology Pharmaceuticals
 - Other Biotechnology Pharmaceuticals
- Regional Concentration

PRIVATE COMPANY PROFILES

Preliminary List of Tables

MARKET OVERVIEW

- 1 Health Care Indicators
- 2 Pharmaceuticals Demand by Type
- 3 Biotechnology Pharmaceuticals
 - Demand by Product Group
- 4 Biotechnology Pharmaceuticals
 - Demand by Indication

INDUSTRY STRUCTURE

- 1 Recent Private & Start-Up Biotechnology Pharmaceutical Company Acquisitions
- 2 Recent Biotechnology Pharmaceutical Company IPO Activity
- 3 Selected Private & Start-Up AIDS/HIV Biotechnology Pharmaceutical Firms
- 4 Selected Private & Start-Up Cancer Biotechnology Pharmaceutical Firms
- 5 Selected Other Private & Start-Up Biotechnology Pharmaceutical Firms

Preliminary List of Charts

MARKET OVERVIEW

- 1 Biotechnology Pharmaceuticals
 - Demand by Technology, 1999

INDUSTRY STRUCTURE

- 1 Market Shares of Selected Biotechnology Pharmaceutical Companies, 1999
- 2 Geographic Distribution of Private & Start-Up Biotechnology Pharmaceutical Companies

Preliminary List of Private Companies Profiled

Abgenix Incorporated
Achillion Pharmaceuticals Incorporated
Acorda Therapeutics Incorporated
Adolor Corporation
AGY Therapeutics Incorporated
Allos Therapeutics Incorporated
AlphaVax Incorporated
Anadys Pharmaceuticals Incorporated
Annovis Incorporated
Antigenics Incorporated
Applied Molecular Evolution Incorporated
Arcaris Incorporated
Arena Pharmaceuticals Incorporated
Argonex Incorporated
Array BioPharma Incorporated
AtheroGenics Incorporated
Athersys Incorporated
Avecia Incorporated

Bio Science Contract Production Corporation
BioMarin Pharmaceutical Incorporated
BioMedicines Incorporated
BioNumerik Pharmaceuticals Incorporated
BioStratum Incorporated
Boehringer Ingelheim Corporation

Calydon Incorporated
Ciblex Corporation
Coley Pharmaceutical Group
Collateral Therapeutics Incorporated
Copernicus Therapeutics Incorporated

Dendreon Corporation
Discovery Therapeutics Incorporated
Dynavax Technologies Corporation

Elitra Pharmaceuticals
Enanta Pharmaceuticals Incorporated
eNOS Pharmaceuticals Incorporated
Eos Biotechnology Incorporated
EPIcyte Pharmaceutical Incorporated
Epimmune Incorporated
Esperion Therapeutics Incorporated
Evolutionary Genomics Incorporated

GeneTrol Biotherapeutics Incorporated
Generic Incorporated
GenVec Incorporated
GlycoTech Corporation
GPC Biotech Incorporated

Hawaii Biotechnology Group Incorporated
Huntsman Corporation

ICAGEN Incorporated
Idun Pharmaceuticals Incorporated
Immtech International Incorporated
Inhibitex Incorporated
Insmid Incorporated
Inspire Pharmaceuticals Incorporated
Integrated Biomolecule Corporation
InterMune Pharmaceuticals Incorporated
IntraBiotics Pharmaceuticals Incorporated
INTRACEL Corporation
Introgen Therapeutics Incorporated
Ista Pharmaceuticals Incorporated

Jenner Biotherapies Incorporate

Kinetix Pharmaceuticals Incorporated
Kosan Biosciences Incorporated

MAXIA Pharmaceuticals Incorporated
Maxygen Incorporated
The Medicines Company
Meiogen Biotechnology Corporation
Memory Pharmaceuticals Corporation
MERIX Bioscience Incorporated
Metabasis Therapeutics Incorporated
Metabolex Incorporated
MitoKor
MoliChem Medicines Incorporated
Mountain View Pharmaceuticals Incorporated
Myelos Corporation
Myogen Incorporated

Neuron Therapeutics Incorporated
New Century Pharmaceuticals Incorporated
NitroMed Incorporated
Nobex Corporation
Northwest Biotherapeutics Incorporated

Octamer Incorporated
Origen Therapeutics Incorporated
Otogene USA Incorporated

Panacea Pharmaceuticals Incorporated
Pharmadyne Incorporated
Pharmasset Incorporated
Phytera Incorporated
Pilot Therapeutics Incorporated
POZEN Incorporated
Praecis Pharmaceuticals Incorporated
ProdiGene Incorporated
Protein Pathways Incorporated
Protein Sciences Corporation
Prototek Incorporated
Purdue Pharma LP

Quorex Pharmaceuticals Incorporated

Raven Biotechnologies Incorporated
Rigel Pharmaceuticals
RxKinetix Incorporated

Sangamo BioSciences Incorporated
Seattle Genetics Incorporated
Sensus Drug Development Corporation
SRA Life Sciences Incorporated
Sunesis Pharmaceuticals Incorporated
Symbiotics Incorporated
Synthon Chiragenics Corporation

Tanox Incorporated
Targesome Incorporated
Telik Incorporated
Therion Biologics Corporation
TransMolecular Incorporated
TransTech Pharma Incorporated
Tularik Incorporated

UroGenesys Incorporated

VaxGen Incorporated
VistaGen Incorporated

X-Ceptor Therapeutics Incorporated
Xcyte Therapies Incorporated

Zarix Incorporated

The Freedomia Group: Private Companies Report #1363 - "Biotechnology Pharmaceuticals"

PRIVATE COMPANY PROFILES

Otogene USA Incorporated
4010 Stone Way North, Suite 120
Seattle, WA 98103
County: King
County Code: 53033

Phone: 206-634-2559
Fax: 206-634-2245
Web Address:

Annual Sales: \$11,000,000
Employment: 100 (11/00)
Principal Owner: Otogene AG
Key Executive: Jonathan Kil, President

Key Products: development of biomedical therapeutic products for hearing impairment

Census Code SIC(s): 8731
SIC Description(s): commercial physical and biological research

Otogene, a subsidiary of Otogene AG (Germany), develops biomedical therapeutic products designed to correct the biological cause of hearing impairment. Otogene has developed molecules that modulate the function of gene products necessary to stimulate the regeneration of cells that are essential for hearing. Systems for delivering therapeutic to target cells within the inner ear have also been designed. Otogene, which has filed patent applications for many of its proprietary screening and assay technologies, plans to enter preclinical testing on its drug candidates in 2001. The Company intends to market its products in the US, Japan and the European Community.

© Copyright by The Freedomia Group, Inc.

Information in profiles obtained from primary sources. Sales and/or employment figures verified by majority of companies

Profiles include:

- 20+ AID/HIV biotechnology pharmaceutical companies
- 70+ cancer biotechnology pharmaceutical companies
- 100+ other biotechnology pharmaceutical companies

* Every attempt has been made to profile all US-based private companies with corporate sales in excess of \$50 million.

More than 110 private and start-up company profiles, ranging from detailed descriptions (over 95% of profiles) to brief company overviews

INDUSTRY STRUCTURE

TABLE III-5
(continued)

SELECTED OTHER PRIVATE & START-UP BIOTECHNOLOGY PHARMACEUTICAL COMPANIES

Company	Corporate Sales (mil \$)*	Indication					Technology					
		Antibiotic/Antifungal	Diabetes	Hepatitis	Heart Disease	Neurological Conditions	Other/Unspecified	Combinatorial Chemistry	Gene Therapy	Monoclonal Antibodies	Recombinant DNA	Other/Unspecified
Evolutionary Genomics												
GeneTrol Biotherapeutics												
Generic												
GenVec												
GlycoTech												
GPC Biotech	4											
Hawaii Biotechnology Group	<2											

PRIVATE COMPANY PROFILES

Eos Biotechnology Incorporated (continued)

associated with cancer and other diseases. Eos will then use Medarex's monoclonal antibody technology, known as HuMAB-MOUSE, to create fully human antibodies to those targets. The initial product resulting from this

PRIVATE COMPANY PROFILES

Eos Biotechnology Incorporated

225A Gateway Boulevard
South San Francisco, CA 94080
County: San Mateo
County Code: 06081

Phone: 650-246-2300
Fax: 650-583-3881
Web Address:

Annual Sales: \$11,000,000
Employment: 100 (11/00)
Key Executive: Jonathan Kil, President and CEO

Key Products: development of novel therapeutic and diagnostic products through the application of high-throughput genomics, bioinformatics and biological processes; and commercialization of reagents

Census Code SIC(s): 8731
SIC Description(s): commercial physical and biological research

Eos Biotechnology is engaged in the development of novel therapeutic and diagnostic products through the application of high-throughput genomics, bioinformatics and biological processes. The Company's initial product development efforts are in therapeutic antibodies. Eos also operates a reagents division which is involved in the commercialization of reagents for the research laboratory market. Eos' largest shareholders are Affymetrix Incorporated, Bay City Capital, ProQuest Investments, Venrock Associates and Zesiger Capital Group. In September 2000, Eos completed a private equity financing which raised \$28 million. Participants included existing investors, as well as the Company's corporate collaborators and new investors. A September 1999 private equity placement of Eos' preferred stock raised \$27 million.

In February 2000, Eos formed a strategic partnership with Medarex Incorporated (Princeton, New Jersey), which represented Eos' first major alliance for the discovery and development of antibody therapeutic products. In the multi-year partnership, Eos is to identify and validate novel antibody targets

continued . . .

© Copyright by The Freedomia Group, Inc.

Order Information

To order fill out the coupon below and mail to The Freedonia Group, or place your order by phone **toll free (800) 927-5900** (US) or **(440) 684-9600**, or by fax **(440) 646-0484**, or by e-mail **info@freedoniagroup.com**

Free Handling and Shipping

There is **NO** charge for handling and UPS shipping in the US. Expect delivery in 3 to 5 days. Outside the US, Freedonia provides free airmail service. If you require express delivery, Freedonia provides this to you at cost.

Save Five Percent

If your order is accompanied by a check, you may take a **5% cash discount**. If you order three (3) different titles at the same time, you can receive a 15% discount.

Credit Card Orders

You may charge your order to either **Visa, MasterCard** or **American Express**. Please include your credit card account number, expiration date and your signature.

Orders Outside of the US

Checks must be paid in US funds, drawn against a US bank and mailed directly to The Freedonia Group. Wire transfers (include study # and/or invoice #) should be sent to: Fifth Third Bank, Cincinnati, OH, SWIFT No. FTBCUS3C, ABA #042000314, Account #83051814 (please include study number and/or invoice number with all wire transfers). Or you may use a credit card.

Online Access

The complete text and tables from our studies and reports can be accessed on our Web site **www.freedoniagroup.com** and through major commercial online hosts.

Other titles from The Freedonia Group

Biochips

The US biochip market - poised to take advantage of the flood of information from the Human Genome Project - will reach \$1.7 billion in 2004. Explosive growth will be led by a range of applications in biomedical research that streamline the drug discovery process and create more powerful tools for diagnosis, disease management, and toxicological monitoring. This study analyzes the US biochip industry to 2004 and 2009 by type, application and market. It also evaluates market share and profiles key firms.

#1365 12/2000 \$3600

Biotechnology in Agriculture – Private Companies Report

Most firms active in the \$1.6 billion US agricultural biotechnology industry are privately-held and/or start-ups, the top two of which had total revenues of at least \$25 million in 1999. An additional 21 such companies had total sales of at least \$25 million, including revenues not related to ag biotech. This report profiles over 100 private US ag biotech companies (e.g., Cargill, EDEN Bioscience). The report also includes market shares, recent acquisitions and IPOs, cooperative agreements, and industry forecasts.

#1349 11/2000 \$3200

Biotechnology Pharmaceuticals

US demand for biotech drugs will grow almost 13% annually. Gains will be driven by new products as continuing advances in biotechnology enable drug researchers to develop safe and effective medicines for conditions not adequately treated with conventional pharmaceuticals. Faster regulatory review will also benefit demand. This study analyzes the \$15.7 billion US biotech drug industry to 2004 and 2009 by type, technology and application. It also presents market share and profiles key companies.

#1338 10/2000 #3700

In Vitro Diagnostics - Private Companies Report

Four private US producers had total *in vitro* diagnostics (IVD) sales of at least \$50 million in 1999. The largest of these is one of the seven leading IVD manufacturers in the US. Private producers also hold significant positions as suppliers of particular

types of IVD equipment. This report profiles over 100 private US firms (e.g., bioMerieux, Nova Biomedical, Dade Behring, Home Diagnostics). The report also reviews acquisitions, forecasts industry demand and lists firms by product and location.

#1333 10/2000 \$3200

Industrial & Specialty Enzymes

Specialty and industrial enzymes demand in the US will grow over 7% annually, spurred by the advent of novel biocatalysts targeted at a myriad of end uses (e.g., textiles, cosmetics). Medical and diagnostic enzymes will remain the leading end use by value. The enzyme industry will continue to benefit from biotechnology-based approaches to production. The study details the \$1.8 billion US enzymes industry to 2004 and 2009 by product and market. It also presents market share and profiles key firms.

#1318 09/2000 \$3500

Pharmaceutical Chemicals

US demand for pharmaceutical chemicals will increase 7% annually. Bulk hormones and related agents will see the fastest growth based on new bioengineered compounds for cancer, diabetes and infertility. Respiratory chemicals will also do well spurred by improved asthma and allergy therapies. This study analyzes the \$14.6 billion US pharmaceutical chemicals industry to 2004 and 2009 by therapeutic class, regulatory status, and production source. It also presents market share data and profiles key industry players.

#1311 08/2000 \$3800

Chiral Chemicals

The US market for chiral chemicals will grow nearly 10% annually, driven by regulatory and competitive incentives to improve active drug ingredients. Pharmaceutical chemicals will be the largest and fastest growing market. Leading non-drug markets include amino acids for polymers, along with enzymes and peptides for medical diagnostic and research investigations. This study analyzes the \$6 billion US chiral chemicals industry to 2003 and 2008. It also presents market share data and profiles selected companies.

#1182 09/1999 \$3500

ORDER FORM

Name: _____

Title: _____

Company: _____

Division: _____

Street: _____
(no PO Box please)

City/State/Zip: _____

Country: _____

Phone: _____ Fax: _____

e-mail: _____

TITLE

Biotechnology Pharmaceuticals – Private Companies Report

PRICE

\$3200

Additional copies are \$390 each per title Total: \$ _____

Enclosed is my check (5% discount) drawn on a US bank and payable to The Freedonia Group, Inc., in US funds (Ohio residents add 7% sales tax)

Bill my company American Express MasterCard Visa

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Credit Card #

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Expiration Date

Signature: _____

The Freedonia Group, Inc. 767 Beta Drive Cleveland, OH 44143-2326 USA web site: www.freedoniagroup.com
phone: 800-927-5900 (US) or 440-684-9600 fax: 440-646-0484 e-mail: info@freedoniagroup.com